Absci collaborates with AstraZeneca for AI-designed oncology antibody
Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, announced a groundbreaking collaboration with AstraZeneca, a global biopharmaceutical company. This partnership aims to develop an AI-designed antibody targeting oncology, potentially accelerating the discovery of a new cancer treatment candidate. Financial Commitment and Collaboration Details The agreement encompasses an upfront commitment, along with R&D […]